The DOI matches its Crossref record.
Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity.
Abstract
OBJECTIVE: Insulin resistance is associated with hypofibrinolysis. Metformin has been shown to improve insulin sensitivity and fibrinolysis. Its action on fibrinolysis and the von Willebrand factor was evaluated in the Biguanides and the Prevention of the Risk of Obesity (BIGPRO)1 trial in nondiabetic men (n = 151) and women (n = 306) aged between 34 and 65 years with a central fat distribution and a mean BMI of 32.5 kg/m2. RESEARCH DESIGN AND METHODS: The subjects were randomly allocated to a 1-year treatment with metformin (850 mg b.i.d.) or placebo, in addition to diet and exercise recommendations. RESULTS: Plasminogen activator inhibitor 1 (PAI-1) activity and antigen decreased significantly but similarly by 30 and 40%, respectively, in both the placebo and the metformin groups. This decrease occurred mainly in subjects who lost weight. Metformin did not have any significant additional effect on PAI-1. In contrast to the results for PAI-1, there was a significantly greater decrease in tissue-type plasminogen activator (tPA) antigen in the metformin than in the placebo group (mean+/-SD: -1.1+/-3.1 vs. 0.2+/-3.2 ng/ml, P < 0.02). The von Willebrand factor (vWF) also decreased significantly more in the metformin group (-0.17+/-0.42 vs. -0.05+/-0.38 U/I, P < 0.02). CONCLUSIONS: Weight loss was the main factor associated with the decrease in PAI-1, in accordance with the recent demonstration of production of PAI-1 by adipocytes. Metformin had a significant effect on two factors, tPA antigen and vWF, mainly secreted by the endothelial cells, which suggests an effect of the drug on the production or the metabolism of these two hemostatic proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many different mechanisms, beyond glycemic control, have been implicated in vascular protection induced by metformin such as improvements in the inflammatory pathway [86], coagulation [87], oxidative stress and glycation [88-92], endothelial dysfunction [88-90], haemostasis [88,91-93], insulin resistance improvement [94], lipid profiles [95,96], and fat redistribution [97,98].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [93]
In the citing paper
“Furthermore, plasma levels of PAI-1 and vWF, which are secreted mainly by the impaired endothelium, have been shown to decrease with metformin therapy in non-diabetic subjects [93].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [93]
Citations
Cited by
Sorted by citations
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
“Weight loss was associated with a 30% to 40% decrease in plasminogen activator inhibitor-1 activity, regardless of the method used, whereas metformin produced significantly larger decreases in von Willebrand factor levels than did diet therapy (78).”
BackgroundMethodInfluentialDouketis, J. D., Macie, C., Thabane, L., & Williamson, D. F. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802982 · Cited by 665
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus
Mather, K. J., Verma, S., & Anderson, T. J. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01129-9 · Cited by 513
Endothelial Dysfunction in Obesity and Insulin Resistance: A Road to Diabetes and Heart Disease
Caballero, A. E. (2003) · Obesity Research · doi:10.1038/oby.2003.174 · Cited by 416
Obesity, haemostasis and the fibrinolytic system
Mertens, I. L., & Gaal, L. F. V. (2002) · Obesity Reviews · doi:10.1046/j.1467-789x.2002.00056.x · Cited by 368
Hundal, R. S., & Inzucchi, S. E. (2003) · Drugs · doi:10.2165/00003495-200363180-00001 · Cited by 315
Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1
Skurk, T., & Hauner, H. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802778 · Cited by 303
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus
Salpeter, S. R., Buckley, N. S., Kahn, J. A., & Salpeter, E. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.09.016 · Cited by 248
de Jager, J., Kooy, A., Lehert, P., Bets, D., Wulffelé, M. G., Teerlink, T., Scheffer, P. G., Schalkwijk, C., Donker, A. J. M., & Stehouwer, C. D. A. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01420.x · Cited by 222
Effects of Lifestyle on Hemostasis, Fibrinolysis, and Platelet Reactivity: A Systematic Review
Lee, K. W., & Lip, G. Y. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.19.2368 · Cited by 217
Coagulation and fibrinolysis abnormalities in obesity
De Pergola, G., & Pannacciulli, N. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03344054 · Cited by 206
Preiss, D., Lloyd, S. M., Ford, I., McMurray, J. J., Holman, R. R., Welsh, P., Fisher, M., Packard, C. J., & Sattar, N. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70152-9 · Cited by 187
Plasma von Willebrand factor, thrombosis, and the endothelium: The first 30 years
Blann, A. D. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-07-0527 · Cited by 175
Caballero, A. E., Delgado, A., Aguilar-Salinas, C. A., Herrera, A. N., Castillo, J. L., Cabrera, T., Gomez-Perez, F. J., & Rull, J. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0019 · Cited by 151
de Jager, J., Kooy, A., Schalkwijk, C., van der Kolk, J., Lehert, P., Bets, D., Wulffelé, M. G., Donker, A. J., & Stehouwer, C. D. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12128 · Cited by 129
Predisposing factors to post-operative adhesion development
Fortin, C., Saed, G. M., & Diamond, M. P. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv021 · Cited by 118
“This improvement occurs in the form of decreased PAI-1 levels and increased tPA activity (Juhan-Vague and Alessi, 1996; Charles et al., 1998).”
BackgroundCaballero, A. E. (2004) · Current Diabetes Reports · doi:10.1007/s11892-004-0074-9 · Cited by 114
“In the obese nondiabetic subjects included in the BIGPRO-1 (Biguanides and the Prevention of the Risk of Obesity) study, metformin led to a reduction in PAI-1 levels in an association with weight loss [ 70 ].”
BackgroundMetformin as Treatment for Overweight and Obese Adults: A Systematic Review
Levri, K. M. (2005) · The Annals of Family Medicine · doi:10.1370/afm.343 · Cited by 104
Xu, L., Borges, M. C., Hemani, G., & Lawlor, D. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4396-y · Cited by 104
Mechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview
Correia, S. C., Carvalho, C., Santos, M. S., Seiça, R. M. F., Oliveira, C. R., & Moreira, P. I. (2008) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955708786369546 · Cited by 98
“Furthermore, this drug affects the coagulation system inducing a reduction in fibrinogen [126] and von Willebrand factor (vWF) levels [127].”
BackgroundInsulin resistance syndrome: interaction with coagulation and fibrinolysis
Köhler, H.-P. (2002) · Swiss Medical Weekly · doi:10.4414/smw.2002.09856 · Cited by 95
“The effects of weight change and metformin on fibrinolysis and the vWF in obese non-diabetic subjects have been investigated [ 82 ].”
BackgroundTreatment of insulin resistance in diabetes mellitus
Lebovitz, H. E., & Banerji, M. A. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.051 · Cited by 96
Wang, L., Chen, L., Liu, Z., Liu, Y., Luo, M., Chen, N., Deng, X., Luo, Y., He, J., Zhang, L., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01087 · Cited by 86
“PAI-1 has also been demonstrated within adipose tissue, with adipocytes being a major source of production for circulating PAI-1 in obese individuals (Folsom et al., 1993; Charles et al., 1998; Eriksson et al., 1998).”
BackgroundPharmacological and surgical treatment of obesity.
Shekelle, P., Morton, S. C., Maglione, M., Suttorp, M. J., Tu, W., Li, Z., Maggard, M. A., Mojica, W., Shugarman, L. R., & Solomon, V. (2004) · PubMed · Cited by 80
Caballero, A. E. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.03.013 · Cited by 82
Plutzky, J., Viberti, G. C., & Haffner, S. M. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(02)00202-7 · Cited by 81
“Reductions in PAI-1 levels with metformin therapy have been shown in both obese nondiabetic individuals (Charles et al., 1998) and patients with type 2 diabetes (Testa et al.”
BackgroundMcCallister, J. W., Adkins, E. J., & O’Brien, J. M. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.05.008 · Cited by 76
“VWF is also increased in obesity (45) and appears to be linked to insulin resistance and endothelial dysfunction (46).”
BackgroundMetformin: Intrinsic Vasculoprotective Properties
Wiernsperger, N. F. (2000) · Diabetes Technology & Therapeutics · doi:10.1089/15209150050025230 · Cited by 75
Madsen, K. S., Chi, Y., Metzendorf, M.-I., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008558.pub2 · Cited by 70
Eschwège, É. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(03)72784-0 · Cited by 66
Self-citationAso, Y., Matsumoto, S., Fujiwara, Y., Tayama, K., Inukai, T., & Takemura, Y. (2002) · Metabolism · doi:10.1053/meta.2002.31334 · Cited by 65
Bagg, W., Ferri, C., Desideri, G., Gamble, G. D., Ockelford, P., & Braatvedt, G. D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8035 · Cited by 66
Industry funding and the reporting quality of large long-term weight loss trials
Thomas, O., Thabane, L., Douketis, J. D., Chu, R., Westfall, A. O., & Allison, D. B. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.137 · Cited by 64
Hemmingsen, B., Sonne, D. P., Metzendorf, M., & Richter, B. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012151.pub2 · Cited by 76
Metformin as a Potential Agent in the Treatment of Multiple Sclerosis
Dziedzic, A., Saluk, J., Miller, E. D., & Bijak, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175957 · Cited by 62
Charles, M.-A. A., Eschw�ge, E., Grandmottet, P., Isnard, F., Cohen, J., Bensoussan, J.-L., Berche, H., Chapiro, O., Andr�, P., Vague, P., et al. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(200001/02)16:1 · Cited by 58
Self-citationRole of von Willebrand factor in vascular disease
Paulinska, P., Spiel, A. O., & Jilma, B. (2009) · Hämostaseologie · doi:10.1055/s-0037-1616936 · Cited by 57
Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes
Henry, R. R. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80242-4 · Cited by 55
Holland, W. L., Morrison, T. E., Chang, Y., Wiernsperger, N., & Stith, B. J. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.02.016 · Cited by 57
Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis
Tkáč, I. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.002 · Cited by 54
Fontbonne, A., Diouf, I., Baccara-Dinet, M., Eschwege, E., & Charles, M.-A. (2009) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.03.005 · Cited by 53
Self-citationThe cardioprotective effects of marrubiin, a diterpenoid found in Leonotis leonurus extracts
Mnonopi, N., Levendal, R., Davies‐Coleman, M. T., & Frost, C. L. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.08.041 · Cited by 53
Pathophysiology and treatment of the dyslipidemia of insulin resistance
Cohn, G., Valdes, G., & Capuzzi, D. M. (2001) · Current Cardiology Reports · doi:10.1007/s11886-001-0059-0 · Cited by 49
Kain, K., Catto, A. J., & Grant, P. J. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00958.x · Cited by 48
Tsikouris, J. P., Suarez, J. A., & Meyerrose, G. E. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002762491271 · Cited by 49
Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus
Škrha, J., Prázný, M., Hilgertová, J., Kvasnička, J., Kalousová, M., & Zima, T. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0378-1 · Cited by 48
“The effect of metformin on lowering tPA and vWF concentrations was previously described in obese, nondiabetic patients [30].”
BackgroundKishore, P., Li, W., Tonelli, J., Lee, D.-E., Koppaka, S., Zhang, K., Lin, Y., Kehlenbrink, S., Scherer, P. E., & Hawkins, M. A. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000292 · Cited by 48
Liu, Y., Wang, L., Luo, M., Chen, N., Deng, X., He, J., Zhang, L., Luo, P., & Wu, J. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00387.2018 · Cited by 44
“Furthermore, circulating PAI-1 levels correlate with the amounts of visceral fat, suggesting that the adipose tissue is the primary source of the production of PAI-1 in obese individuals (5, 11, 12).”
BackgroundAlruwaili, M., Al-Kuraishy, H. M., Alexiou, A. T., Papadakis, M., Alrashdi, B. M., Elhussieny, O., Saad, . M., & Batiha, G. E. (2023) · Neurochemical Research · doi:10.1007/s11064-023-03981-1 · Cited by 45
Ansari, G., Mojtahedzadeh, M., Kajbaf, F., Najafi, A., Khajavi, M. R., Khalili, H., Rouini, M. R., Ahmadi, H., & Abdollahi, M. R. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0075-1 · Cited by 43
Differential Effects of Oral Hypoglycemic Agents on Glucose Control and Cardiovascular Risk
Uwaifo, G. I., & Ratner, R. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.006 · Cited by 43
Abdelgadir, E., Ali, R., Rashid, F., & Bashier, A. M. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2922e · Cited by 45
“Nonetheless, metformin was found to reduce the levels of plasminogen activator inhibitor-1, and Von Willibrand factor from the unhealthy endothelium in patients with no underlying diabetes mellitus [35].”
BackgroundTREATMENT FOR THE PROCOAGULANT STATE IN TYPE 2 DIABETES
Colwell, J. A. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70225-5 · Cited by 41
Use of Metformin in Patients with Kidney and Cardiovascular Diseases
Klachko, D. M., & Whaley‐Connell, A. T. (2011) · Cardiorenal Medicine · doi:10.1159/000327151 · Cited by 37
“Therapy with metformin also reduces the thrombogenic propensity by decreasing levels of tissue plasminogen activator antigen and von Willebrand factor [”
BackgroundPalamara, K., Mogul, H. R., Peterson, S. J., & Frishman, W. H. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000233903.57946.fd · Cited by 36
Sudi, K. M., Gallistl, S., Tröbinger, M., Payerl, D., Weinhandl, G., Muntean, W. E., Aigner, R., & Borkenstein, M. H. (2001) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2001.14.1.85 · Cited by 35
Dietary treatment of thrombogenic disorders related tothe metabolic syndrome
Marckmann, P. (2000) · British Journal of Nutrition · doi:10.1017/s0007114500001057 · Cited by 37
A marriage of two “Methusalem” drugs for the treatment of psoriasis?
Glossmann, H. H., & Reider, N. (2013) · Dermato-Endocrinology · doi:10.4161/derm.23874 · Cited by 32
“Significant decreases of tissue-type plasminogen activator inhibitor and of von Willebrand factor were later confirmed in a randomized double-blind controlled trial with obese subjects but no overt diabetes.(121) Other symptoms of the metabolic syndrome, such as higher systolic blood pressure and elevated LDL-choleste…”
BackgroundOral antidiabetic agents as cardiovascular drugs
Macfarlane, D. P., Paterson, K., & Fisher, M. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00592.x · Cited by 31
Insulin Resistance, ADMA Levels, and Cardiovascular Disease
Nash, D. T. (2002) · JAMA · doi:10.1001/jama.287.11.1451 · Cited by 31
Haber, R., Zarzour, F., Ghezzawi, M., Saadeh, N., Bacha, D. S., Jebbawi, L. A., Chakhtoura, M., & Mantzoros, C. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15501 · Cited by 35
“47,51,55,56,61,73,74,76,77,79,83,84,89 A post hoc subgroup analysis according to the presence or absence of NAFLD showed no significant difference in the change in fasting insulin levels (data not shown).”
BackgroundAn investigation into the pleiotropic activity of metformin. A glimpse of haemostasis
Markowicz-Piasecka, M., Sadkowska, A., Huttunen, K. M., Podsiedlik, M., Mikiciuk‐Olasik, E., & Sikora, J. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.172984 · Cited by 31
Lu, D., Huang, C., Huang, P., Chung, C., Lin, S., Chen, J., Chan, W., & Leu, H. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-187 · Cited by 29
Zangeneh, F., Kudva, Y. C., & Basu, A. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.4.471 · Cited by 31
Cardiovascular disease and heritability of the prothrombotic state
Ajjan, R., & Ariëns, R. A. S. (2008) · Blood Reviews · doi:10.1016/j.blre.2008.07.001 · Cited by 27
Metformin and Carbohydrate-Modified Diet: A Novel Obesity Treatment Protocol
Mogul, H. R., Peterson, S. J., Weinstein, B. I., Zhang, S., & Southren, A. L. (2001) · Heart Disease · doi:10.1097/00132580-200109000-00002 · Cited by 27
Seherawat, A. (2014) · IOSR Journal of Environmental Science Toxicology and Food Technology · doi:10.9790/2402-08545155 · Cited by 25
Acidose lactique et metformine
Orban, J., Ghaddab, A., Chatti, O., & Ichaï, C. (2006) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2006.05.009 · Cited by 25
Is metformin more than an oral hypoglycaemic agent?
Vague, P. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(03)72782-7 · Cited by 23
Self-citationFantoni, M., Borgo, C. D., & Autore, C. (2003) · AIDS · doi:10.1097/00002030-200304001-00020 · Cited by 23
“In the same study, HIV-infected patients with fat redistribution and insulin resistance showed a significant reduction of insulin area under the curve, tPA and PAI-1 after 12 weeks of therapy with low-dose metformin, as was previously shown in HIV-negative patients [48,49].”
ResultLongo‐Mbenza, B., On'kin, J. B. K. L., Okwe, A. N., & Kabangu, N. K. (2010) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2010.05.009 · Cited by 22
Effects of diet with or without exercise on leptin and anticoagulation proteins levels in obesity
Murakami, T., Horigome, H., Tanaka, K., Nakata, Y., Katayama, Y., & Matsui, A. (2007) · Blood Coagulation & Fibrinolysis · doi:10.1097/01.mbc.0000278929.87251.5d · Cited by 22
Plasma Protein Oxidation as a Determinant of Impaired Fibrinolysis in Type 2 Diabetes
Bryk, A. H., Konieczyńska, M., Rostoff, P., et al. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1676609 · Cited by 22
Metformin Does Not Adversely Affect Hormonal and Symptomatic Responses to Recurrent Hypoglycemia
Fruehwald‐Schultes, B., Kern, W., Oltmanns, K. M., Sopke, S., Toschek, B., Jan Born, A., Fehm, H. L., & Peters, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7790 · Cited by 23
Gardner, A. W., & Killewich, L. A. (2002) · Angiology · doi:10.1177/000331970205300401 · Cited by 21
Charles, M.-A. A., & Eschw??ge, E. (1999) · Drugs · doi:10.2165/00003495-199958001-00015 · Cited by 21
Self-citationMarkowicz-Piasecka, M., Huttunen, K. M., Mateusiak, Ł., Mikiciuk‐Olasik, E., & Sikora, J. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.02.012 · Cited by 20
Gedawy, A., Al‐Salami, H., & Dass, C. R. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0102 · Cited by 19
Forouhi, N. G., Rumley, A., Lowe, G. D. O., McKeigue, P., & Sattar, N. A. (2003) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-200312000-00011 · Cited by 20
Mertens, I. L., van der Planken, M., Corthouts, B., & Gaal, L. F. V. (2006) · Metabolism · doi:10.1016/j.metabol.2006.01.001 · Cited by 19
Thiazolidinediones and Insulin
Huang, A., & Raskin, P. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504040-00002 · Cited by 19
Yener, S., Çömlekçi, A., Akıncı, B., Akan, P., Demir, T., Bayraktar, F., & Yeşil, S. (2008) · HORMONES · doi:10.14310/horm.2002.1111039 · Cited by 18
Hörber, S., Lehmann, R., Fritsche, L., Machann, J., Birkenfeld, A. L., Häring, H., Stefan, N., Heni, M., Fritsche, A., & Peter, A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab124 · Cited by 17
Is Metformin Cardioprotective?
Sasali, A., & Leahy, J. L. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.243 · Cited by 16
Alterations of coagulation in metformin intoxication
Akıncı, B., Yener, S., Bengı, G., & Yeşil, S. (2008) · HORMONES · doi:10.14310/horm.2002.1214 · Cited by 16
“Metformin improves impaired fibrinolytic activity in type 2 diabetes.(7,8) It moreover improves fibrinolytic activity in non-diabetic subjects.”
BackgroundMetabolic syndrome therapy: Prevention of vascular injury by antidiabetic agents
Dominguez, L. J., & Sowers, J. R. (2005) · Current Hypertension Reports · doi:10.1007/s11906-005-0083-3 · Cited by 14
Perriello, G., Pampanelli, S., Brunetti, P., Pietro, C. D., & Mariz, S. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.044 · Cited by 14
Alipanahzadeh, H., Ghulamreza, R., Shokouhian, M., Bagheri, M., & Maleknia, M. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-02005-6 · Cited by 13
“In addition, hypofibrinolysis induced by insulin resistance is another cause of DVT in these patients [81].”
BackgroundRole of clotting factors and fibrin structure in predisposition to atherothrombotic disease
Ajjan, R., & Grant, P. J. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.6.1047 · Cited by 12
Díez, R., Garcia, J. J., Diez, M. J., Sierra, M., Sahagún, A. M., & Fernández, N. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-1809-x · Cited by 11
“Besides these important antidiabetic effects, which have been manifest utility in patients with type 2 diabetes [3] and in preventing it in patients with obesity and insulin resistance [4], metformin has actions on body weight [5], serum lipids level [6], blood pressure [7], vascular effect [8], nitroxidative and oxid…”
BackgroundThe Pharmacologic Basis for the Treatment of Endocrinopathic Laminitis
Durham, A. E. (2010) · Veterinary Clinics of North America Equine Practice · doi:10.1016/j.cveq.2010.04.006 · Cited by 9
The Cumulative Incidence and Risk Factors of Recurrent Venous Thromboembolism in the Elderly
Aleidan, F. A. S. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s264814 · Cited by 9
McCarty, M. F. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.03.038 · Cited by 9
Antidiabetes drug metformin is a donor of nitric oxide: EPR measurement of efficiency
Сереженков, В. А., Кузнецов, И. С., Romantsova, T. I., Кузнецова, М., & Vanin, A. F. (2011) · BIOPHYSICS · doi:10.1134/s0006350911060169 · Cited by 9
Metabolic complications of glucocorticoids – Prevention by metformin
Sanpawithayakul, K., & Korbonits, M. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.05.002 · Cited by 9
Evaluation of the Association Metformin:Plantago ovataHusk in Diabetic Rabbits
Díez, R., Garcia, J. J., Diez, M. J., Sierra, M., Sahagún, A. M., Calle, Á. P., & Fernández, N. (2015) · Journal of Diabetes Research · doi:10.1155/2015/167526 · Cited by 6
Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients
Kebapçılar, L., Kebapçılar, A. G., Bilgir, O., Taner, C. E., Bozkaya, G., Yıldız, Y., & Sarı, İ. (2010) · Gynecological Endocrinology · doi:10.3109/09513590.2010.491164 · Cited by 6
“Plasma levels of PAI-1 and vWF, which are secreted mainly by impaired endothelium, have been shown to decrease with metformin therapy in non-diabetic subjects [21,22].”
BackgroundDiagnosis and Management of Horses with Equine Metabolic Syndrome (EMS)
Chameroy, K. A. (2010) · Cited by 3
Metadata
- Authors
- Charles, M. A., Morange, P., Eschwège, E., André, P., Vague, P., & Juhan-Vague, I.
- Affiliations
- Inserm (FR)
- INSERM (National Institute of Health and Medical Research) Unit 21, Villejuif, France. charles@vjf.inserm.fr
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 1998-11-01
- Volume
- 21
- Issue
- 11
- Pages
- 1967-1972
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2054703675
- Cited by
- 120
- References
- 0
- Citations by year
- 2024: 3 · 2023: 2 · 2021: 1 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 4 · 2016: 1 · 2015: 3 · 2014: 4 · 2013: 5
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Hematology › Blood properties and coagulation
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- metformin, weight loss, fibrinolysis, von Willebrand factor, plasminogen activator inhibitor-1, tissue plasminogen activator, obesity, insulin resistance, abdominal obesity, adipocytes, endothelial cells, hemostatic proteins
- MeSH terms
- Adult, Aged, Female, Fibrinolysis, Hemostasis, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Obesity, Triglycerides, von Willebrand Factor, Weight Loss, Plasminogen Activator Inhibitor 1, Tissue Polypeptide Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
